AKTS today
$17.04-$0.41 (-2.35%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourLeaning Bearish
15 minStrong Bearish
5 minAscending Triangle
Daily trend turns up above $33.53
Key levels
Resistance$18.96
Resistance$17.33
Support$15.59
Support$13.96
Latest news & SEC filings
EarningsAktis Oncology posts wider quarterly loss, revenue below estimates
SEC FilingAktis Oncology, Inc. filed a report on a major company event (Form 8-K)
AnalystWedbush Reiterates Outperform Rating on Aktis Oncology, Keeps $35 Price Target
ProductAktis Oncology begins second Phase 1b trial of AKY-2519
All AKTS news →About Aktis Oncology
Aktis Oncology is a clinical-stage oncology company developing targeted radiopharmaceuticals. Its main candidates are miniprotein radioconjugates that deliver alpha-emitting isotopes to solid tumors, led by one aimed at Nectin-4 and another at B7-H3. The company also has a discovery collaboration with Eli Lilly. It operates in the United States and relies on isotope suppliers and contract manufacturers for its supply chain.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
Aktis Oncology, Inc. (AKTS)
What Is the Price Target for AKTS?
SEPT Low Target
$33.00
SEPT Mid Target
$35.00
SEPT High Target
$40.00
Analyst Consensus
$35.00
Is AKTS a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AKTS.
Start Free Trial →Is AKTS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$35.00
19
Moat Score
NONE
5/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with AKTS?
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Czibere Akos | officer | Buy | 12,500 | $62K | Sep 23, 2026 |
| Czibere Akos | officer | Sale | 5,099 | $103K | Sep 23, 2026 |
| Czibere Akos | officer | Sale | 7,401 | $156K | Sep 23, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AKTS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for AKTS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AKTS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:37:34 | $17.25 | 1,207 | $$21K | SELL |
| 15:22:34 | $17.69 | 1,049 | $$19K | BUY |
| 19:54:20 | $17.13 | 7,173 | $$123K | MIDPOINT |
| 16:04:19 | $16.82 | 1,000 | $$17K | MIDPOINT |
| 16:04:17 | $16.82 | 3,200 | $$54K | MIDPOINT |
5 dark pool trades shown · $$233K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Aktis Oncology, Inc. (AKTS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AKTS — frequently asked questions
What is AKTS stock price today?
Aktis Oncology, Inc. (AKTS) is at $17.04, down 2.35% (-$0.41) at the Nov 11, 2026 close.
Why is AKTS stock moving today?
Latest AKTS news — Nov 12, 2026: Aktis Oncology posts wider quarterly loss, revenue below estimates · Nov 12, 2026: Aktis Oncology, Inc. filed a report on a major company event (Form 8-K)
What is the AKTS price target?
The average analyst price target for AKTS is $35.00, ranging from $33 to $40, based on 7 analysts.
What do analysts rate AKTS?
Analyst ratings for AKTS: 0 Buy, 9 Hold, 0 Sell — consensus Hold.
Did AKTS beat earnings?
AKTS last reported on Aug 13, 2026: EPS -$0.44 vs -$0.43 expected — a miss of 2.2%.
Does AKTS pay a dividend?
AKTS does not currently pay a dividend.
What are AKTS support and resistance levels?
Support: $15.59, $13.96. Resistance: $17.33, $18.96, $20.08.
What are insiders doing with AKTS?
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
What is the latest news on AKTS?
Nov 12, 2026: Aktis Oncology posts wider quarterly loss, revenue below estimates · Nov 12, 2026: Aktis Oncology, Inc. filed a report on a major company event (Form 8-K) · Oct 2, 2026: Wedbush Reiterates Outperform Rating on Aktis Oncology, Keeps $35 Price Target